Eli Lilly (LLY) on Friday received a European Medicines Agency warning that Mounjaro (tirzepatide) may affect oral contraceptive reliability, with women advised to use backup contraception or switch to non-oral methods.
The EMA's Committee for Medicinal Products for Human Use adopted a direct healthcare professional communication recommending barrier contraception for four weeks after starting Mounjaro and for four weeks after each dose increase, citing limited data on tirzepatide's effects on oral contraceptive efficacy.
Eli Lilly shares were 0.3% higher in premarket trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments